Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Podobne knjige/članki

• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  od: Raedler, Lisa A.
  Izdano: (2015)
• Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
  od: Raedler, Lisa A.
  Izdano: (2015)
• Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
  od: Raedler, Lisa A.
  Izdano: (2015)
• Pembrolizumab (Keytruda)
  od: Kwok, Gerry, et al.
  Izdano: (2016)
• Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
  od: Raedler, Lisa A.
  Izdano: (2016)